Drugs / Opal-HIV-Gag(c)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01123915 | May 2010 → Dec 2011 | HIV infectious disease | Medicines Development for Global Health | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Opal-HIV-Gag(c) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01123915 ↗ |
| Modality | Vaccine | “We performed a phase I, single centre, placebo-controlled, double-blinded and dose-escalating study to evaluate the safety and preliminary immunogenicity of a novel therapeutic...” PMID 24124451 ↗ Oct 2013 |
| Route | Intravenous | “Treatment was administered intravenously after bedside enrichment of 120 mL whole blood for white cells using a closed system (Sepax S-100 device), with ex vivo peptide...” PMID 24069230 ↗ Sep 2013 |